Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Cooley

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Plos One|August 29, 2012
Developmental dynamics of post-selection thymic DN iNKTMaryam Yassai, Brian Cooley, Jack Gorski
Thrombosis Research|December 29, 2015
In vitro and in vivo characterization of a reversible synthetic heparin analogMatthew F Whelihan, Brian Cooley, Yongmei Xu, et al.
The Iowa Orthopaedic Journal|November 19, 2011
Efficacy and cost-effectiveness of a blood salvage system in primary total knee arthroplasty--a retrospective match-controlled chart reviewClifford Kent Boese, Theresa J Gallo, Marcia Weis, et al.
Blood|April 18, 2019
Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B modelBrian Cooley, George J Broze, David M Mann, et al.
The Journal of Surgical Research|September 25, 2010
The effects of BleedArrest, Celox, and TraumaDex on hemorrhage control in a porcine modelBrian Gegel, James Burgert, Brian Cooley, et al.
Blood|April 24, 2016
Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B miceBrian Cooley, William Funkhouser, Dougald Monroe, et al.
Journal of the American Chemical Society|March 25, 2017
Synthesis of 3-O-Sulfated Oligosaccharides to Understand the Relationship between Structures and Functions of Heparan SulfateZhangjie Wang, Po-Hung Hsieh, Yongmei Xu, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 22, 2019
Choosing a Mouse Model of Venous ThrombosisJose A Diaz, Prakash Saha, Brian Cooley, et al.
Journal of Thrombosis and Haemostasis : JTH|March 31, 2019
Choosing a mouse model of venous thrombosis: a consensus assessment of utility and applicationJose A Diaz, Prakash Saha, Brian Cooley, et al.
Thrombosis Research|May 30, 2018
The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarctionMichael F Bode, Alyson C Auriemma, Steven P Grover, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Plos One|August 29, 2012
Developmental dynamics of post-selection thymic DN iNKTMaryam Yassai, Brian Cooley, Jack Gorski
Thrombosis Research|December 29, 2015
In vitro and in vivo characterization of a reversible synthetic heparin analogMatthew F Whelihan, Brian Cooley, Yongmei Xu, et al.
The Iowa Orthopaedic Journal|November 19, 2011
Efficacy and cost-effectiveness of a blood salvage system in primary total knee arthroplasty--a retrospective match-controlled chart reviewClifford Kent Boese, Theresa J Gallo, Marcia Weis, et al.
Blood|April 18, 2019
Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B modelBrian Cooley, George J Broze, David M Mann, et al.
The Journal of Surgical Research|September 25, 2010
The effects of BleedArrest, Celox, and TraumaDex on hemorrhage control in a porcine modelBrian Gegel, James Burgert, Brian Cooley, et al.
Blood|April 24, 2016
Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B miceBrian Cooley, William Funkhouser, Dougald Monroe, et al.
Journal of the American Chemical Society|March 25, 2017
Synthesis of 3-O-Sulfated Oligosaccharides to Understand the Relationship between Structures and Functions of Heparan SulfateZhangjie Wang, Po-Hung Hsieh, Yongmei Xu, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|February 22, 2019
Choosing a Mouse Model of Venous ThrombosisJose A Diaz, Prakash Saha, Brian Cooley, et al.
Journal of Thrombosis and Haemostasis : JTH|March 31, 2019
Choosing a mouse model of venous thrombosis: a consensus assessment of utility and applicationJose A Diaz, Prakash Saha, Brian Cooley, et al.
Thrombosis Research|May 30, 2018
The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarctionMichael F Bode, Alyson C Auriemma, Steven P Grover, et al.
Pageof 2